Hims & Hers Health Stock: A Good Investment for Filipinos in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Hims & Hers Health for over three years. Every month, hundreds of thousands of users in the Philippines trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Hims & Hers Health.

What is Hims & Hers Health?

What is the price of Hims & Hers Health stock?

The price of Hims & Hers Health stock is rising this week. As of now, the share trades at $51.24, gaining +4.66% over the last 24 hours and up 6.26% for the week. Market capitalization is $11.47 billion, with a robust 3-month average volume of 46.18 million shares. The P/E ratio stands at 75.35, with no dividend yield at present, and the beta is 2.07, underlining substantial volatility. Such dynamic movement reflects both growth opportunities and higher risk, making it important for PH investors to stay informed.

Our full analysis of Hims & Hers Health stock

After a comprehensive review of Hims & Hers Health's most recent financial results and stock performance over the past three years, our analysis draws upon a blend of the latest financial indicators, technical signals, market sentiment, and detailed competitor benchmarking. By applying proprietary algorithms to this data-rich context, we aim to cut through the market noise and provide a clear, actionable perspective. So, why might Hims & Hers Health stock once again become a strategic entry point into the fast-evolving digital health sector in 2025?

Recent performance and market context

Hims & Hers Health has delivered a stellar stock performance, up by a remarkable 147.7% over the past year, with the price recently reaching $51.24 as of July 9, 2025. The most recent week saw an impressive +6.26% gain, and the stock outperformed its sector peers following a surge of +99% over the past six months. Positive sentiment has been fueled by robust earnings, an adjusted EBITDA surge to $91.1 million in Q1 2025, and management’s clear guidance for annual revenues to hit $2.3–2.4 billion this year. The company remains well-capitalized, with a current market capitalization of $11.47 billion, and enjoys a growing userbase now exceeding 2.4 million subscribers.

Recent positive milestones include the completion of the high-profile ZAVA acquisition, expanding its presence in the European telehealth market, and the strategic announcement of an international push into Canada scheduled for 2026. The overall macro backdrop for telehealth and direct-to-consumer medicine remains highly favorable, driven by digitalization and the increasing willingness of global and Philippine consumers alike to seek digital-first, trusted healthcare solutions. Such trends indicate that Hims & Hers Health is riding a potent, secular wave of adoption.

Technical analysis

Technical signals confirm a strong underlying structure for Hims & Hers Health. The RSI sits at 50.49, reflecting a neutral but constructive momentum positioning—suggesting the stock is neither overbought nor oversold. Meanwhile, after a recent consolidation, the price has continued to track above its long-term 100- and 200-day moving averages ($44.03 and $35.23, respectively), reinforcing a medium- and long-term bullish bias. With MACD modestly negative but stabilizing, the groundwork appears set for the next upward leg should bullish catalysts materialize.

Key support is identified at $25.00, offering robust downside protection following earlier breakouts, while resistance at $67.00 aligns with consensus analyst targets. Most notably, the consistent ability of the stock to remain above major moving averages underscores investor conviction and suggests the sustainability of the ongoing uptrend. For technicians, such a posture often foreshadows renewed momentum in the medium term.

Fundamental analysis

Fundamentals underpin the positive argument for Hims & Hers Health. Q1 2025 revenue jumped to $586 million, a year-on-year leap of 111%—well above consensus—and net income reached $49.5 million, reflecting strong management execution and business model resilience. Profitability metrics have consistently impressed, with adjusted EBITDA moving from $32.3 million last year to $91.1 million this quarter.

Despite a high Price/Earnings Ratio of 75.35, this valuation is justified by the company’s extraordinary growth rate, the scalability of its subscription model, and expectations for sustained revenue acceleration. Its strong market positioning, as the clear leader in direct-to-consumer digital health in the US and poised for European and Canadian expansion, amplifies the long-term investment case.

Structural strengths include:

• Consistent double-digit subscriber growth, further consolidating market share.
• Rapid diversification beyond GLP-1-based treatments, with innovative healthcare solutions.
• Recurring and scalable subscription revenue, supporting robust cashflow.
• Recognized brand equity and a best-in-class tech-enabled healthcare platform.

In a space where market share and network effects dominate, Hims & Hers Health appears singularly well-positioned for the next phase of digital health innovation.

Volume and liquidity

Share liquidity and trading volumes are at healthy levels, with an average 3-month volume of 46.18 million shares. This demonstrates ample market confidence and facilitates ease of entry or exit, a boon for both institutional and retail investors. The current float remains favorable to continued dynamic valuation, supporting the company’s ability to attract new capital while generating ongoing market interest.

Such volume ensures that investors in the Philippines and globally can gain exposure at competitive spreads, with lower risk of price slippage. This, in turn, signals strong institutional presence and reinforces the quality of the uptrend.

Catalysts and positive outlook

A combination of organic business drivers and new catalysts continues to tip the outlook for Hims & Hers Health in a bullish direction. The successful acquisition of ZAVA, accelerating penetration into the European telemedicine market, provides a tangible path for new revenue streams and geographic diversification. The announced 2026 move into Canada aligns smartly with the expiration of the Novo Nordisk semaglutide patent, opening the door for future generic entry in a large adjacent market.

Other forward drivers include:

• Sustained innovation in digital patient experience and personalized health.
• Ongoing expansion in the US, European, and soon Canadian markets.
• Growth in high-margin, custom treatment solutions beyond the GLP-1 weight care segment.
• Strong ESG profile with a commitment to accessible healthcare services, resonating with younger, values-driven consumers.
• A robust cash position to support further M&A or organic growth initiatives.

Favorable sector winds are at the back of telehealth and digital medicine, with regulators and governments supporting access, and consumers prioritizing personalized, flexible healthcare experiences.

Investment strategies

For investors seeking strategic entry, Hims & Hers Health presents arguments for different investment horizons:

• Short-term: The recent consolidation phase and relative strength above moving averages may offer tactical buying opportunities, especially around support zones below $50.
• Medium-term: The Q2 earnings release and newsflow regarding Canadian expansion present clear catalysts for potential re-rating and upward moves toward consensus price targets (currently $66.61, which is +30% from the latest close).
• Long-term: Secular trends in telehealth, expected international growth, and recurring revenue streams signal an outstanding risk/reward profile for patient, growth-oriented investors.

Ideal portfolio positioning could involve accumulating the stock during technical pauses or ahead of validated business milestones—such as regulatory or commercial updates linked to international expansion.

Is it the right time to buy Hims & Hers Health?

Recent performance and sharply improved financials, coupled with high conviction technical and fundamental signals, all point to a stock entering a new bullish phase. The fundamentals justify renewed interest—from the company’s leadership in the US telehealth space and expanding global footprint, to its best-in-class digital platform and powerful network effects. Even at elevated valuation multiples, the pace of revenue and earnings growth, alongside the execution of international scaling, suggests Hims & Hers Health seems to represent an excellent opportunity for investors.

While all stocks require ongoing diligence, Hims & Hers Health continues to check the boxes for a potential leader in digital health innovation. Its bullish catalysts, liquidity, structural advantages, and innovative momentum make it a stock that deserves careful consideration—especially for investors in the Philippines keen on global growth stories in healthcare and technology.

With its impressive growth trajectory, market support, and multiple catalysts on the horizon, Hims & Hers Health stands out as a stock that may be entering a defining phase—one where upside potential could reward those who seek out the next leaders of the digital health revolution.

How to buy Hims & Hers Health stock in the Philippines?

Buying Hims & Hers Health stock online is simple and secure when you use a regulated broker. As a retail investor in the Philippines, you can choose between two main methods: a classic “spot” purchase of shares for straightforward ownership, or trading via Contracts for Difference (CFDs) to benefit from price moves with leverage. Both options allow access to US-listed stocks from your phone or computer. To ensure you get the best value, a full broker comparison is provided further down the page.

Spot buying

A cash purchase means you directly buy Hims & Hers Health shares and become their rightful owner. Typically, Philippine brokers charge a fixed commission per trade, often around ₱250–₱300 per order (about $5).

Gain scenario

If the Hims & Hers Health share price is $51.24, you can buy around 19 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Buying stocks outright is ideal for long-term investors who want to own part of the company and benefit from potential appreciation.

Trading via CFD

CFD trading lets you speculate on the price movements of Hims & Hers Health shares without actually owning them. With CFDs, fees come mainly from the bid-ask spread and potential overnight financing costs if you hold your position for more than a day.

Gain Scenario with a Leveraged CFD Position

You open a CFD position on Hims & Hers Health shares, with 5x leverage. This gives you a market exposure of $5,000.

✔️ Gain scenario:

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

CFDs amplify your capital’s potential gains—as well as its risks—so they are best suited for active or advanced traders.

Final advice

Before investing, always compare the fees, security, and features of different brokers to find the best fit for your needs. Your choice between cash buying and CFDs should match your risk preference and financial objectives. For help choosing, check out the broker comparison table provided below on this page.

7 Tips for Buying Hims & Hers Health Stock

The latest news about Hims & Hers Health

Hims & Hers Health stock surged 6.26% this week, supported by strong technical and performance indicators. Shares closed at $51.24, with intraday gains of 4.66% and the company outperforming the broader market for the past six months (+99%) and year (+147%). The price remains above long-term moving averages (100/200-day), signaling a solid structural uptrend and increasing investor confidence in sustained growth.

Q1 2025 earnings exceeded analyst forecasts, highlighting exceptional revenue and net income growth. Hims & Hers Health reported Q1 revenue of $586 million, representing a 111% year-over-year increase, with adjusted EBITDA surging to $91.1 million from $32.3 million last year. Net income reached $49.5 million. This performance continued a multi-quarter trajectory of surpassing expectations, strengthening the stock’s attractiveness for international and Philippine investors looking at high-growth digital health names.

The company announced international expansion plans into Canada in 2026, fueling optimism about future regional growth potential. With the patent expiry for semaglutide, Hims & Hers Health expects to offer more affordable generics, aligning with the rising demand for accessible telehealth and digital medical services in North America and, by extension, influencing trends and sector valuations relevant for Southeast Asian markets like the Philippines.

Acquisition of European telehealth firm ZAVA positions Hims & Hers Health for accelerated global expansion and service diversification. By integrating ZAVA, the company is poised to extend its reach into the European market. This strategic move broadens its telehealth portfolio and diversifies revenue sources beyond GLP-1 weight loss medications, which is increasingly important for growth outlooks tracked by Philippine-based global investors.

Market sentiment remains optimistic despite recent partnership challenges, with subscriber numbers reaching 2.4 million and a robust growth outlook for 2025. Hims & Hers Health continues to diversify beyond weight-loss therapies and telehealth, with guidance for 2025 revenue between $2.3 and $2.4 billion. Maintained optimism is especially relevant to Philippine analysts drawing parallels to digital health sector trends, robust earnings momentum, and expanding global footprints.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.